AC Immune SA (ACIU) has released an update.
AC Immune SA has entered into a significant Option and License Agreement with Takeda Pharmaceuticals, USA, Inc., granting Takeda an exclusive option to license AC Immune’s intellectual property for the development, manufacture, and commercialization of specific compounds and products. The agreement, effective as of May 11, 2024, details the terms and conditions under which Takeda can exercise this option, symbolizing a strategic collaboration between the two companies in the pharmaceutical industry.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
